<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this article was to explore the pathogenetic differences, as well as to provide a new way for the differential diagnosis of these two diseases by comparative analysis of CD(34)(+) cells numbers and their surface expression of granulocyte colony-stimulating factor receptor (G-CSFR) and granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR) in patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-seven patients with AA, 45 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and 20 <z:mpath ids='MPATH_458'>normal</z:mpath> controls were enrolled in this study </plain></SENT>
<SENT sid="2" pm="."><plain>The ratio of CD(34)(+) cells and their surface expression of G-CSFR and GM-CSFR were detected by flow cytometry (FCM) </plain></SENT>
<SENT sid="3" pm="."><plain>The ratio of CD(34)(+) cells in BMMNC of AA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and controls were 0.2438 +/- 0.1129%, 2.1677 +/- 1.1345% and 1.0792 +/- 0.3221%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Compared with <z:mpath ids='MPATH_458'>normal</z:mpath> controls as well as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, the ratio of CD(34)(+) cells in BMMNC of AA was significantly reduced (P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>The ratio of CD(34)(+) cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was significantly elevated than controls (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>The ratio of CD(34)(+) cells in BMMNC of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> patients were 1.2821 +/- 0.4658% and 3.7729 +/- 2.3360%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Compared with <z:mpath ids='MPATH_458'>normal</z:mpath> controls and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA patients, the ratio of CD(34)(+) cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> was significantly elevated (P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>The ratio of CD(34)(+) cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA was significantly elevated than AA patients (P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>The surface expression of G-CSFR on CD(34)(+) cells of AA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and controls were 34.402 +/- 21.8357%, 26.376 +/- 15.2895% and 21.443 +/- 7.4465%, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>The surface expression of G-CSFR on CD(34)(+) cells of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> patients were 22.788 +/- 14.7628% and 30.682 +/- 15.5346% </plain></SENT>
<SENT sid="11" pm="."><plain>The surface expression of GM-CSFR on CD(34)(+) cells of AA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and controls were 6.5961 +/- 4.4322%, 18.2737 +/- 10.9841% and 4.2753 +/- 2.6249%, respectively </plain></SENT>
<SENT sid="12" pm="."><plain>Compared with AA and controls, the expression of GM-CSFR in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients was significantly elevated (P &lt; 0.05) </plain></SENT>
<SENT sid="13" pm="."><plain>The surface expression of GM-CSFR on CD(34)(+) cells of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> patients were 16.1625 +/- 6.9487% and 22.1003 +/- 14.2983% </plain></SENT>
<SENT sid="14" pm="."><plain>In AA patients, the ratio of CD(34)(+) cells in BMMNC less than 0.1% accounts for 75% (6/8) SAA patients, compared with 10.55% (2/19) in CAA (P &lt; 0.05) </plain></SENT>
<SENT sid="15" pm="."><plain>The detection of CD(34)(+) cells and their surface expression of granulocyte (macrophage) colony-stimulating factor receptors G (M)-CSFR in AA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are helpful in the differential diagnosis or prognosis of these two disorders </plain></SENT>
</text></document>